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Background
Atrial fibrillation (AF) coincides with coronary artery 
disease (CAD) given common risk factors and patho-
physiologic pathways. CAD affects approximately 
every fourth AF patient according to the trial Atrial 
Fibrillation Follow-up Investigation of Rhythm Man-
agement (AFFIRM), while in the Global Registry of 
Acute Coronary Events (GRACE) atrial fibrillation af-
fected about 9% of patients with CAD [1–3]. The opti-
mal medical regimen in these patients remains a 
matter of debate. This is particularly true for patients 
undergoing percutaneous coronary intervention 
(PCI) and require antiplatelet therapy. We reported 
the prevalence of AF in patients undergoing percuta-
neous coronary intervention (PCI) to be approxi-
mately 5% [4]. Combination of vitamin K antagonists 
(VKA) with antiplatelet treatment imposes an addi-
tional risk of bleeding. Finding a safe and effective 
balance between the risk of ischaemic events and 
bleeding complications is challenged by shared risk 
factors for either event such as advanced age, hyper-
tension, or renal disease. Triple antithrombotic ther-
apy with acetylsalicylic acid, clopidogrel, and VKA 
has been associated with a considerable risk of bleed-
ing events in patients with myocardial infarction 
and stable coronary artery disease [4, 5]. Dual ther-
apy with clopidogrel and VKA has been documented 
to offer favourable safety and efficacy outcomes as 
compared to triple therapy [6, 7].
Percutaneous left atrial appendage occlusion (LAAO) 
is a proven alternative to oral anticoagulation in pa-
tients with nonvalvular AF [8, 9]. With longer fol-
low-up in the randomised PROTECT-AF trial, LAAO 
showed superiority over VKA with regard to cardio-
vascular death and a trend towards better stroke pre-
vention [10]. In a high-risk population, such as AF-pa-
tients undergoing PCI, LAAO may be an attractive 
treatment option by obviating the need for com-
bined oral anticoagulation and antiplatelet therapy.
The objective of the present analysis was therefore to 
Summary
Aims: To investigate feasibility and safety of concomitant percutaneous 
coronary intervention (PCI) and left atrial appendage occlusion (LAAO) as 
compared to PCI in combination with antithrombotic treatment in patients 
with coronary artery disease and nonvalvular atrial fibrillation (AF).
Methods and results: Patients with AF undergoing concomitant PCI with 
drug-eluting stents (DES) and LAAO with dedicated devices were consec-
utively entered into a prospective single-centre registry and were com-
pared to AF patients from the Bern DES registry treated with different 
antithrombotic strategies. Among 379 patients with AF, 56 patients were 
treated with concomitant PCI and LAAO, 268 patients were treated with 
PCI and dual therapy (DT), and 55 patients were started on triple anti-
thrombotic therapy (TT). Clinical follow-up was assessed by standardised 
telephone interviews. Patients with PCI + LAAO were older (76 ± 7 years) 
as compared to patients with PCI + DT (72 ± 9 years) or PCI + TT (73 ± 8 
years) (p <0.01). They more commonly had a history of cerebrovascular 
events (31% vs 10% vs 16%, p <0.001). CHA
2
DS
2
-vasc scores amounted to 
3.5 ± 2.2, 3.6 ± 1.3, and 4.2 ± 1.3 among patients with PCI + LAAO, PCI + DT, 
and PCI + TT, respectively (p = 0.03). At 30 days, the composite of all-cause 
death, myocardial infarction, ischemic stroke, or BARC bleeding type 3–5 
was documented in 12.5% of patients undergoing PCI + LAAO, 8.2% in pa-
tients with PCI + DT, and 9.2% in patients with PCI + TT, with no significant 
differences between groups in an age-adjusted analysis (PCI + DT being 
the reference; PCI + LAAO: HR 1.27 (95% CI 0.54–2.99), p = 0.58; PCI + TT 
(1.19 [95% CI 0.49–2.92], p = 0.70). Two patients (3.6%) with PCI + LAAO suf-
fered a periprocedural stroke, and 5 patients (8.9%) were recorded to have 
bleeding BARC type 3a or 3b. At 1 year, all-cause mortality in patients with 
PCI + DT, amounted to, 6.7% (reference). It was 6.3% (HR 0.51, 95%CI 0.12–
2.20, p = 0.36) and 18.2% (HR 2.89, 95% CI 1.33–6.26, p <0.01) in PCI + LAAO 
and PCI + TT, respectively. There was no difference with regards to the 
composite of all-cause death, myocardial infarction, ischaemic stroke, or 
bleeding (BARC type 3–5) (PCI + DT being the reference; PCI + LAAO: HR 
1.17 (95% CI 0.56–2.45), p = 0.67; PCI + TT (1.68 [95% CI 0.89–3.15], p = 0.11).
Conclusion: PCI with concomitant LAAO is a feasible alternative to com-
bined anti-platelet and anti-thrombotic management in patients with CAD 
and AF. Longer-term follow-up will be needed to demonstrate efficacy. 
Key words: left atrial appendage occlusion; atrial fibrillation; coronary heart disease; percutaneous 
coronary intervention; antiplatelet therapy; anticoagulation; drug-eluting stents
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investigate clinical outcome of patients with CAD un-
dergoing PCI and nonvalvular AF according to treat-
ment with dual-antiplatelet therapy in combination 
with LAAO (PCI + LAAO), dual therapy (PCI + DT), or 
triple therapy (PCI + TT).
Methods
Patient Population
All patients with nonvalvular AF and CAD leading to 
PCI with DES were prospectively entered into a data-
base at Bern University Hospital, Switzerland, be-
tween April 2002 and March 2009. Patients with AF 
and CAD undergoing PCI and LAAO with dedicated 
devices were enrolled in a prospective clinical regis-
try started in 2009. Written informed consent was 
obtained from all patients. Both registries have been 
approved by the Ethics Committee at Bern University 
Hospital, Switzerland, and complied with the Decla-
ration of Helsinki.
Procedures
PCI procedure
PCI was performed in accordance with current stand-
ards of care. A femoral access was chosen in all pa-
tients. In some patients undergoing elective PCI, VKA 
was discontinued 3 days prior to the procedure in or-
der to achieve an International Normalised Ratio 
(INR) <2.0. In particular, patients presenting with 
acute coronary syndromes underwent PCI without a 
VKA-free interval and regardless of INR measure-
ment. During the procedure, all patients were loaded 
with acetylsalicylic acid 250–500 mg and unfraction-
ated heparin in a dose of 70–100 IU/kg or at least 
5000 IU. The consecutive antiplatelet and anticoagu-
lation therapy was installed upon the discretion of 
the operator. After the procedure a control electro-
cardiogram was performed in all patients and cre-
atine kinase (CK), CK-MB, and troponin T were as-
sessed to determine peak enzyme levels.
Left atrial appendage occlusion
In patients receiving both PCI and LAAO within the 
same session, PCI was usually performed prior to 
LAAO. A transoesophageal echocardiogram (TOE) 
was performed prior to the procedure to rule out 
thrombus formation in the LAA, except for patients 
undergoing ad-hoc LAAO where thrombus in the left 
atrial appendage was excluded by contrast injection 
to the left atrium [9]. All procedures were performed 
under local anaesthesia with fluoroscopic guidance 
only (no TOE). The Amplatzer Cardiac Plug (ACP, 
St. Jude Medical, Plymouth, MN, USA) was used in all 
patients. The left atrium was accessed either by a 
transseptal puncture or by a patent foramen ovale 
(PFO) or atrial septal defect (ASD) if such was present 
(in which case the defect was closed using an Amp-
latzer PFO or ASD Occluder through the same deliv-
ery sheath at the termination of the procedure). The 
LAA was sized by contrast medium injections 
through the 13 French Amplatzer TorqVue delivery 
sheath (St. Jude Medical, Plymouth, MN, USA) in at 
least 2 projections. The outer diameter of the sheath 
(5.5 mm) served as reference for sizing. The aim was 
to oversize the device by at least 20%. After deploying 
the device a stable position was confirmed by a tug 
test and contrast medium injection.
After the procedure and before hospital discharge, a 
control transthoracic echocardiogram was performed 
to document a stable position of the device. Oral anti-
coagulation was stopped immediately after implanta-
tion in most cases and antiplatelet therapy was in-
stalled according to the discretion of the operator.
Data collection
Follow-up was performed by standardised telephone 
interviews. In patients treated with LAAO, a control 
TOE was performed after 3–6 months to exclude 
 device thrombus and residual leaks and to confirm 
proper sealing of the LAA. In case of a potential ad-
verse event, hospital record documentations from 
primary care physicians and referring cardiologists 
were collected. All cardiac and bleeding events were 
adjudicated by cardiologists and all neurologic 
events by neurologists. All data were entered into a 
dedicated database.
Figure 1: Events per treatment strategy. BARC = bleeding academic research 
 consortium; MI = myocardial infarction.
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Definitions
AF was defined as at least 1 documented episode of ir-
regularly irregular rhythm of at least 30 seconds du-
ration. We did not differentiate between intermit-
tent, persistent, or permanent AF for the purpose of 
this analysis. Triple therapy was defined as the com-
bination of acetylsalicylic acid, clopidogrel, and VKA. 
Dual therapy was defined as VKA in combination 
with acetylsalicylic acid or clopidogrel or the combi-
nation of two platelet inhibitors. Cardiac death was 
defined as death resulting from cardiac reasons, pro-
cedure-related mortality, or death of unknown cause. 
Myocardial infarction (MI) encompassed Q-wave and 
non-Q-wave MI and was documented with the pres-
ence of new pathological Q-waves in ≥2 contiguous 
leads or elevation of CK to ≥2 × upper limit of normal 
(ULN) and a rise in CK-MB or troponin to ≥3 × ULN. 
Neurologic events were classified into transient is-
chaemic attack (TIA), ischaemic stroke, or unclear 
neurologic events. Transient ischaemic attack was 
defined as a focal neurologic deficit that resolved 
completely within 24 hours and showed no signs of 
ischaemia in computed tomography or magnetic res-
onance imaging. Ischaemic stroke was defined as a 
focal neurologic deficit persisting for >24 hours or 
with the evidence of a corresponding ischaemic le-
sion in an imaging examination. A neurologic event 
was classified as unclear when patients reported neu-
rologic symptoms but there was no documentation 
which would allow further classification into stroke 
or TIA. Bleeding events were adjudicated according to 
the definitions provided by the bleeding academic 
research consortium (BARC) [11].
Statistical analysis
Baseline characteristics of patients were first de-
picted for 3 groups according to the treatment they 
received concomitantly with PCI. Discrete data were 
summarised as counts and frequencies (%) with 
p-values from Chi-Square, whereas continuous data 
were presented as means ± SD with p-values from 
ANOVAs. Counts of clinical outcomes and their inci-
dence rates from Kaplan-Meier life tables were then 
displayed. Cox regressions were performed to com-
pute hazard ratios of clinical outcomes at 30 days and 
1-year follow-up, PCI + DT being the reference group. 
Adjustment was done for age as well as for other 
baseline characteristics (age, gender, CHA
2
DS
2
-vasc 
score, and left ventricular ejection fraction). Two-
sided p-values less than 0.05 were considered as sta-
tistically significant. All analyses were performed us-
ing Stata version 13.0.
Results
A total of 379 patients with AF and CAD undergoing 
PCI were included into the present analysis. Of them, 
56 patients with AF deemed at increased risk of bleed-
ing were treated with concomitant PCI + LAAO and 
no further VKA, 268 patients were treated with dual 
therapy (DT; 195 [73%] with double antiplatelet treat-
ment, and 73 [27%] with VKA and single antiplatelet 
therapy) and 55 patients were treated with VKA, ace-
tylsalicylic acid, and clopidogrel (TT). Baseline char-
acteristics are summarised in table 1. Patients treated 
with PCI + LAAO were older than patients treated 
with PCI + DT or PCI + TT (76 ± 7 versus 72 ± 9 versus 73 
Table 1: Baseline characteristics.     
Baseline characteristics PCI + LAAO PCI + DT PCI + TT p-value
N = 379 N = 56 N = 268 N = 55  
Age years (SD) 76.4 ± 7.2 72.0 ± 9.1 73.1 ± 8.1 0.003
Sex, male n (%) 14 (25.0%) 68 (25.4%) 18 (32.7%) 0.513
BMI mean kg/m
2
 (SD) 27.7 ± 4.6 27.0 ± 4.5 28.7 ± 5.4 0.086
Cardiovascular risk factors     
  Hypertension n (%) 52 (92.9%) 171 (63.8%) 42 (76.4%) <0.001
  Diabetes mellitus n (%) 18 (32.1%) 52 (19.4%) 16 (29.1%) 0.055
Clinical features     
  Renal failure (creatinine ≥200 μmol/l) n (%) 7 (12.7%) 4 (1.7%) 1 (2.0%) <0.001
  Congestive heart failure 9 (21.4%) 110 (41.0%) 26 (47.3%) 0.025
  Prior stroke or TIA 13 (31.0%) 26 (9.7%) 9 (16.4%) 0.001
  LV ejection fraction mean (SD) 54.3 ± 11.7 50.7 ± 12.6 48.4 ± 14.3 0.082
CHA
2
DS
2
2.9 ± 1.3 1.9 ± 1.2 2.3 ± 1.2 <0.001
CHA
2
DS
2
-vasc score 3.5 ± 2.2 3.6 ± 1.3 4.2 ± 1.3 0.030
Depicted are means ± SD with p-values from ANOVAs, or counts (%) with p-values from chi-square tests.
BMI = Body-Mass-Index; LV = left ventricle; TIA = transient ischaemic attack.
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Table 2: Clinical outcome.
Clinical Outcome 
 
All patients
N = 379
PCI+LAAO
N = 56
PCI+DT
N = 268
PCI+TT
N = 55
30-day follow-up     
Death n (%) 12 (3.2) 0 (0.0)  7 (2.6)  5 (9.1)
Cardiac events     
 Cardiac death n (%)  9 (2.4) 0 (0.0)  5 (1.9)  4 (7.4)
 Myocardial infarction (MI) n (%) 10 (2.7) 0 (0.0) 10 (3.7)  0 (0.0)
– Q-wave MI n (%)  5 (1.3) 0 (0.0)  5 (1.9)  0 (0.0)
– Non Q-wave MI n (%)  5 (1.3) 0 (0.0)  5 (1.9)  0 (0.0)
Neurologic events     
 Ischaemic stroke  4 (1.1) 2 (3.6)  2 (0.7)  0 (0.0)
 TIA  1 (0.3) 0 (0.0)  1 (0.4)  0 (0.0)
 Unclear neurologic event  0 (0.0) 0 (0.0)  0 (0.0)  0 (0.0)
Bleeding Events 
 BARC 3a 12 (3.2) 4 (7.1)  6 (2.2)  2 (3.6)
 BARC 3b  4 (1.1) 1 (1.8)  3 (1.1)  0 (0.0)
 BARC 3c  0 (0.0) 0 (0.0)  0 (0.0)  0 (0.0)
 BARC 4  1 (0.3) 0 (0.0)  1 (0.4)  0 (0.0)
 BARC 5a  0 (0.0) 0 (0.0)  0 (0.0)  0 (0.0)
 BARC 5b  2 (0.5) 0 (0.0)  1 (0.4)  1 (1.9)
Composite Outcomes     
Death / MI / ischaemic stroke 24 (6.3) 2 (3.6) 17 (6.3)  5 (9.1)
Cardiac death / MI / ischaemic stroke 21 (5.6) 2 (3.6) 15 (5.6)  4 (7.4)
Death / MI / ischaemic stroke / BARC bleeding 3–5 37 (9.8) 7 (12.5) 24 (9.0)  6 (10.9)
Cardiac death / MI/ ischaemic stroke/ BARC bleeding 3–5 34 (9.0) 7 (12.5) 22 (8.2)  5 (9.2)
1-year follow-up     
Death n (%) 30(8.2) 2 (6.3) 18 (6.7) 10 (18.2)
Cardiac events     
 Cardiac death n (%) 17 (4.7) 1 (1.9)  9 (3.4)  7 (13.0)
 Myocardial infarction (MI) n (%) 13 (3.5) 1 (3.4) 11 (4.1)  1 (2.0)
– Q-wave MI n (%)  5 (1.3) 0 (0.0)  5 (1.9)  0 (0.0)
– Non Q-wave MI n (%)  8 (2.2) 1 (3.4)  6 (2.3)  1 (2.0)
Neurologic events     
 Ischaemic stroke  7 (1.9) 2 (3.6)  5 (1.9)  0 (0.0)
 TIA  1 (0.3) 0 (0.0)  1 (0.4)  0 (0.0)
 Unclear neurologic event  0 (0.0) 0 (0.0)  0 (0.0)  0 (0.0)
Bleeding Events     
 BARC 3a 13 (3.5) 4 (7.1)  7 (2.6)  2 (3.6)
 BARC 3b  6 (1.6) 1 (1.8)  4 (1.5)  1 (2.0)
 BARC 3c  1 (0.3) 0 (0.0)  1 (0.4)  0 (0.0)
 BARC 4  1 (0.3) 0 (0.0)  1 (0.4)  0 (0.0)
 BARC 5a  0 (0.0) 0 (0.0)  0 (0.0)  0 (0.0)
 BARC 5b  2 (0.5) 0 (0.0)  1 (0.4)  1 (1.9)
Composite outcomes     
Death / MI / ischaemic stroke 46 (12.5) 5 (8.9) 30 (11.2) 11 (20.0)
Cardiac death / MI / ischaemic stroke 35(9.5) 4 (7.1) 23 (8.6)  8 (14.9)
Death / MI / Ischaemic stroke / BARC bleeding 3–5 60 (16.1) 9 (16.1) 38 (14.2) 13 (23.6)
Cardiac death / MI / ischaemic stroke / BARC bleeding 3–5 50 (13.5) 9 (16.1) 31 (11.6) 10 (18.5)
Depicted are counts (incidence rates % from Kaplan Meier life tables).
BARC = bleeding academic research consortium; MI = myocardial infarction; TIA = transient ischaemic attack
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± 8 years; p = 0.003), respectively, and more com-
monly had a history of previous stroke (31% versus 
10% versus 16%; p = 0.001).
Clinical outcomes at 30 days and at 1 year are shown 
in table 2. At 30 days, the composite of all-cause 
death, myocardial infarction, ischaemic stroke, or 
bleeding type 3–5 according to the BARC definition 
was documented in 12.5% of patients undergoing PCI 
+ LAAO, 8.2% in patients with PCI + DT, and 9.2% in 
patients with PCI + TT, with no significant differences 
between groups in an age-adjusted analysis (PCI + DT 
being the reference; PCI + LAAO: HR 1.27 (95%CI 0.54–
2.99), p = 0.58; PCI and TT (1.19 [95%CI 0.49–2.92], p = 
0.70) (table 3). Two patients (3.6%) with PCI and LAAO 
suffered a periprocedural stroke. One patient devel-
oped acute somnolence, hypotension, and hemiple-
gia during the intervention. A cerebral angiography 
showed no occlusion of major cerebral arteries. 
Symptoms resolved almost completely within 24 
hours; however, at discharge the patient had a resid-
ual mild paresis of the left hand. The second patient 
developed a complete hemiplegia, hemineglect, and 
aphasia the night after the intervention. A CT-scan 
showed a subacute ischaemic insult. On the second 
postinterventional day the patient had a residual 
mild paresis of the hand a central facial nerve pare-
sis, and a gaze paresis. Symptoms improved sponta-
neously until discharge. Five patients (8.9%) were re-
corded as having bleeding BARC type 3a or 3b. At 
1 year, the rate of cardiac death amounted to 1.9%, 
3.4%, and 13.0% in patients with PCI + LAAO, PCI + DT 
and PCI + TT, respectively. The composite of all-cause 
death, MI, ischaemic stroke, and BARC bleeding type 
3–5 was documented in 17.8% of patients with PCI + 
LAAO, 14.2% of patients with PCI+DT, and 23.6% of pa-
tients with PCI + TT. No new bleeding or neurologic 
events were documented in the group of patients 
treated with PCI + LAAO between 30 days and 1 year. 
LAAO and TT were compared with DT in an analysis 
adjusted for age only (table 3) and for all differences 
in baseline characteristics (table 4). There were no 
significant differences with respect to all individual 
and composite endpoints.
Discussion
The key findings can be summarised as follows. (1.) 
Patients with AF and CAD are at high risk of major ad-
verse cardiac, cerebrovascular, or bleeding events 
through 1 year of follow-up; (2.) PCI with concomitant 
Table 3: Age adjusted clinical outcome.
Cox regression with reference group as PCI + DT Age-adjusted analysis
 PCI + LAAO PCI + TT 
 HR (95%CI) p-value HR (95%CI) p-value
30-day follow-up     
Death n.e 3.81 (1.20–12.12) 0.023
Cardiac death n.e 4.05 (1.08–15.14) 0.037
Myocardial infarction n.e  n.e.  
Ischaemic stroke or TIA 2.86 (0.46–17.94) 0.262 n.e.
Ischaemic stroke or MI 089 (0.19–4.11) 0.878 n.e.
BARC bleeding ≥3 1.92 (0.66–5.61) 0.234 1.31 (0.37–4.70) 0.678
Death / MI / ischaemic stroke 0.48 (0.11–2.12) 0.336 1.40 (0.52–3.80 0.507
Cardiac death / MI / ischaemic stroke 0.59 (0.13–2.63) 0.493 1.28 (0.42–3.85) 0.664
Death / MI / ischaemic stroke / BARC bleeding 3–5 1.27 (0.54–2.99) 0.578 1.19 (0.49–2.92) 0.697
Cardiac death / MI / ischaemic stroke / BARC bleeding 3–5 1.45 (0.61–3.45) 0.397 1.16 (0.44–3.07) 0.761
1-year follow-up     
Death n (%) 0.51 80.12–2.209 0.363 2.89 (1.33–6.26) 0.007
Cardiac death n (%) 0.49 (0.06–3.91) 0.499 3.98 (1.48–10.70) 0.006
Myocardial infarction n (%) 0.50 (0.06–4.00) 0.518 0.46 (0.06–3.55) 0.454
Ischaemic stroke or TIA 1.58 (0.31–8.10) 0.584 n.e.
Ischaemic stroke or MI 1.09 (0.31–3.86) 0.894 0.33 (0.04–2.50) 0.283
BARC bleeding ≥3 1.48 (0.53–4.16) 0.455 1.39 (0.46–4.23) 0.559
Death / MI / ischaemic stroke 0.84 (0.32–2.18) 0.714 1.80 (0.90–3.60) 0.095
Cardiac death / MI / ischaemic stroke 0.88 (0.30–2.60) 0.824 1.70 (0.76–3.81) 0.194
Death / MI / ischaemic stroke / BARC bleeding 3–5 1.17 (0.56–2.45) 0.671 1.68 (0.89–3.15) 0.107
Cardiac death / MI / ischaemic stroke / BARC bleeding 3–5 1.43 (0.67–3.05) 0.349 1.72 (0.84–3.50) 0.138
HR are from Cox regression.     
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LAAO is a feasible alternative to combined anti-
thrombotic and antiplatelet therapy and adding the 
risk of an additional and technically demanding pro-
cedure to PCI did not result in a higher complication 
rate; (3.) larger studies with randomised design will 
be needed to assess safety and efficacy of combined 
LAAO and PCI as compared to conventional treat-
ment. 
Our study has several limitations. First, we present a 
historical comparison of patients treated with com-
bined antiplatelet and antithrombotic therapy be-
tween 2002 and 2009 and LAAO between 2009 and 
2013. The recent introduction of non-VKA oral antico-
agulants (NOAC) has led to a paradigm shift in in the 
treatment of nonvalvular AF and has introduced a 
competitive comparator. However, the combination 
of NOAC with antiplatelet agents is not recom-
mended by current guidelines preventing this treat-
ment strategy as an approved comparator at this 
time. Second, the non-randomised treatment alloca-
tion to PCI + LAAO, PCI + DT or PCI + TT introduces a 
selection bias. Due to small numbers of patients, we 
could not perform a propensity score matched analy-
sis. Nonetheless we adjusted the analysis for differ-
ences in baseline characteristics to address the 
non-randomised treatment allocation. However, dif-
ferences between groups may be underestimated by 
latent factors. Third, we included a small number of 
patients with only a short duration of follow-up into 
this analysis. Efficacy of LAAO is expected to have a 
growing advantage over chronic oral anticoagulation 
during long-term follow-up when bleeding complica-
tions in PCI + DT and PCI + TT patients more than out-
weigh the front-loaded procedural complications in 
PCI + LAAO patients.
Studies investigating optimal treatment strategies 
for AF and CAD address the 2 entities isolated from 
each other, thus neglecting the frequent combina-
tion of the 2 diseases. The subset of patients with AF 
and CAD is exposed to an increased risk of ischaemic 
and haemorrhagic events and has an increased risk 
of death as compared to patients with either one of 
the conditions. This is not only explained by the ad-
dition of the individual risk of both disease entities, 
but may also result from a collateral effect of collid-
ing treatment strategies. Aggressive antithrombotic 
Table 4: Baseline variables adjusted clinical outcome.
Cox regression with reference group as PCI + DT
 
 
Baseline characteristics-adjusted analysis*
PCI + LAAO PCI + TT 
HR (95%CI) p-value HR (95%CI) p-value
30-day follow-up     
Death n.e 4.47 (1.31–15.26)  0.017
Cardiac death n.e 4.93 (1.24–19.69) 0.024
Myocardial infarction n.e  n.e.  
Ischaemic stroke or TIA 1.71 (0.21–14.11) 0.621 n.e.
Ischaemic stroke or MI 0.89 (0.18–4.27) 0.883 n.e.
BARC bleeding ≥3 2.12 (0.71–6.30) 0.178 1.21 (0.33–4.37) 0.772
Death / MI / ischaemic stroke 0.55 (0.12–2.42) 0.427 1.30 (0.47–3.54) 0.614
Cardiac death / MI / ischaemic stroke 0.65 (0.14–2.90) 0.571 1.18 (0.39–3.59) 0.770
Death / MI / ischaemic stroke / BARC bleeding 3–5 1.44 (0.61–3.42) 0.404 1.10 (0.45–2.70) 0.840
Cardiac death / MI / ischaemic stroke / BARC bleeding 3–5 1.61 (0.67–3.86) 0.3285 1.00 (0.38–2.66) 0.995
1-year follow-up     
Death n (%) 0.52 (0.11–2.37) 0.399 2.93 (1.33–6.45)  0.008
Cardiac death n (%) 0.40 (0.05–3.53) 0.409 4.33 (1.57–11.95) 0.005
Myocardial infarction n (%) 0.54 (0.07–4.28) 0.556 0.43 (0.05–3.34) 0.417
Ischaemic stroke or TIA 1.33 (0.22–7.98)  0.754 n.e.
Ischaemic stroke or MI 1.17 (0.33–4.22) 0.806 0.29 (0.04–2.19) 0.228
BARC bleeding ≥3 1.52 (0.53–4.39) 0.435 1.35 (0.44–4.14) 0.600
Death / MI / ischaemic stroke 0.96 (0.37–2.54) 0.941 1.68 (0.83–3.37) 0.147
Cardiac death / MI / ischaemic stroke 0.99 (0.33–2.92) 0.979 1.60 (0.71–3.60) 0.258
Death / MI / ischaemic stroke / BARC bleeding 3–5 1.32 (0.63–2.79) 0.460 1.57 (0.83–2.97) 0.164
Cardiac death / MI / ischaemic stroke / BARC bleeding 3–5 1.57 (0.73–3.37) 0.250 1.49 (0.73–3.06) 0.274
HR are from Cox regression.
*The baseline adjusted models control for age, gender, CHA
2
DS
2
-vasc score and left ventricular ejection fraction at baseline. BARC = bleeding aca-
demy research consortium; MI = myocardial infarction; TIA = transient ischaemic attack
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treatment with TT has been shown to increase the 
risk of bleeding complications as compared to VKA 
and acetylsalicylic acid or clopidogrel [5, 7]. The com-
bination of clopidogrel and VKA appeared to offer the 
best balance between benefit and risk.
LAAO has proven effective in patients with AF to the 
end to further reduce the risk of bleeding in this pa-
tient population. Successful device implantation was 
achieved in all patients in our analysis. However, we 
documented a considerable rate of periprocedural 
bleeding in patients with LAAO amounting to 9% 
which was slightly higher than previous reports. Pro-
cedures were performed in consecutive, unselected 
patients (reflecting a real world setting which is often 
associated with higher event rates as compared to 
randomised controlled trials), were combined with 
PCI procedures, and also reflect our ear LAAO experi-
ence with Amplatzer devices. This puts our results 
into proper perspective. As LAAO is a challenging in-
tervention, there may be a rather shallow learning 
curve hampering the clinical outcome of this initial 
series. Besides a relatively high rate of periprocedural 
bleeding events, we observed two peri-interven-
tional strokes (4%). In turn, no new ischaemic or 
haemorrhagic events were documented in the group 
of patients treated with PCI and LAAO between 1 
month and 1 year. In view of the limited number of 
patients this may be a chance finding. On the other 
hand it may also indicate efficacy of LAAO for the pre-
vention of adverse events in this patient population, 
consistent with previous findings in patients with 
isolated AF.
In conclusion, we present an initial series of patients 
treated simultaneously with PCI and LAAO and show 
the feasibility of the concept. Larger studies with ran-
domised design will be required to assess safety and 
efficacy of this approach as compared to medical 
treatment. 
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